BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2021 financial results will be released on Thursday, July 29, after the market closes.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS® (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).

Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases, gene therapies, and complex conditions, announced that it has been selected by Biogen as a specialty pharmacy provider of ADUHELM™.

Regencell Bioscience Holdings Limited announced the pricing of its initial public offering of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share.

FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients.

The minimally invasive neurosurgery is done for treating the diseases that occur in the spinal cord, different parts of the brain, or the skull base.

SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), today announced the signing of an agreement that subject to an approval by the Food & Drug Administration (FDA), will allow AZOVA to sell and distribute SQI’s COVID-19 HOME Antibody Test .

The Sinus Dilation market was valued at US$ 1,918.73 million in 2019 and is projected to reach US$ 3,859.75 million by 2027; it is expected to grow at a CAGR of 9.3% during 2020–2027.

The Medical Recruitment market was valued at US$ 8,684.50 million in 2018 and it is projected to reach US$ 11,435.1 million by 2027; it is expected to grow at a CAGR of 3.1% from 2019 to 2027.

Wugen, Inc. announced the completion of an oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management & Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital.